Nav: Home

A new system for treating type 1 diabetes mellitus

May 10, 2019

Type 1 diabetes mellitus (DMT1) contributes to 10% of the total of cases of diabetes mellitus worldwide, mainly in young people and is regarded as a growing health risk. DMT1 is characterised by the self-immune destruction of the pancreatic cells that produce insulin (pancreatic islets), which leads to severe insulin deficiency and which is followed by the raising of blood glucose levels. Right now, the therapy based on insulin injections is the treatment applied in type 1 diabetic patients. However, in addition to the medical complications this means in the long term, this treatment requires multiple daily measurements of blood glucose and the lifelong sub-cutaneous administration of insulin.

Alternatively, "the transplant of isolated pancreatic islets from donors provides a fresh source of insulin-producing cells capable of meeting insulin requirements in accordance with blood glucose levels in patients with DM1. One of the drawbacks of islet transplants is the long-term use of immunosuppressant drugs to prevent the immune rejection of the transplanted islets; these drugs lower the patient's defences and entail serious medical complications", explained the author of the work Albert Espona-Noguera. "To avoid this problem," he went on, "the pancreatic islets can be isolated from the patient's immune system by means of microencapsulation techniques in which the islets are encapsulated in microcapsules made of biocompatible (non-toxic) materials. Among many materials used in cell microencapsulation, alginate is the most widely used one. This natural polymer has excellent properties for biomedical applications as it offers high compatibility and low toxicity." However, "the microencapsulation technique has various technical obstacles that are hampering its clinical application. A crucial problem is the high number of empty microcapsules generated during the process to microencapsulate the islets, which leads to a large increase in the volume of microcapsules to be implanted, and which in turn may increase the host's immune reaction following implantation," said Espona-Noguera.

Innovative system of magnetic separation

In order to avoid the high number of empty microcapsules, "we have come up with an innovative approach for purifying the microencapsulated islets in order to reduce the implant volume by separating the microencapsulated islets from the empty microcapsules", explained the researcher at the UPV/EHU-Ciber BNN which is part of the Nanbiosis ICTS (Singular Scientific and Technological Infrastructure). "We have developed a system to magnetically separate the microcapsules and which combines different technologies: magnetic nanoparticles and a microfluidic chip, in other words, a chip with channels of micrometric size produced by means of 3D printing techniques and which contains strategically placed magnets," added the researcher. "To separate the microcapsules, the pancreatic islets are put into contact with magnetic nanoparticles, thus providing them with magnetic properties.

After that, the islets are microencapsulated, thus obtaining capsules containing magnetic islets and non-magnetic empty capsules. When the microcapsules are pumped through the chip's microchannels, the magnets move the magnetic capsules towards the exit microchannel, while the non-magnetic empty ones make their way through another exit microchannel," he specified. That way "we are able to eliminate the empty capsules and, as a result, we reduce the volume of the therapeutic microcapsule implant. The great purification efficiency of this magnetic separation system has enabled us to lower the implant volume by nearly 80%, thus reducing the complications arising out of the implanting of large volumes of microcapsules and providing us with an alternative DMT1 treatment", stressed Espona-Noguera.

In addition, "in this work we studied the functionality of the purified implants in diabetic animal models. We saw that following subcutaneous implanting of the microencapsulated islets in diabetic animals, the blood glucose levels returned to normal levels for nearly 17 weeks", he added.
-end-
Bibliographical reference

A. Espona-Noguera, J. Etxebarria-Elezgarai, L. Saenz del Burgo, A. Cañibano-Hernández, H. Gurruchaga, F.J. Blanco, G. Orive, Rosa M. Hernández, F. Benito-Lopez, J. Ciriza, L. Basabe-Desmonts, J.L. Pedraz
Type 1 Diabetes Mellitus reversal via implantation of magnetically purified microencapsulated pseudoislets
International Journal of Pharmaceutics (2019)
DOI: https://doi.org/10.1016/j.ijpharm.2019.01.058

University of the Basque Country

Related Insulin Articles:

Diabetes patients still produce insulin
Some insulin is still produced in almost half of the patients that have had type 1 diabetes for more than ten years.
New type of insulin-producing cell discovered
In people with type I diabetes, insulin-producing beta cells in the pancreas die and are not replaced.
A sustained and controllable insulin release system
Researchers from Kumamoto University, Japan have developed an insulin release system with sustained and controllable delivery.
Chemically modified insulin is available more quickly
Replacing a hydrogen atom by an iodine atom in insulin, the hormone retains its efficacy but is available more rapidly to the organism.
Insulin resistance and polycystic ovary syndrome
Insulin resistance represents a major issue for people with polycystic ovary syndrome (PCOS), an endocrine disorder which is very common in young women, according to a new analysis of available data carried out by Dr.
Insulin resistance reversed by removal of protein
By removing the protein galectin-3 (Gal3), a team of investigators led by University of California School of Medicine researchers were able to reverse diabetic insulin resistance and glucose intolerance in mouse models of obesity and diabetes.
Snails' speedy insulin
University of Utah researchers have found that the structure of an insulin molecule produced by predatory cone snails may be an improvement over current fast-acting therapeutic insulin.
Discovery could lead to treatment to better regulate insulin
A recent discovery made by an Iowa State University professor and a team of researchers holds promise for those who are obese or diabetic and do not benefit from medications to regulate their glucose and insulin levels.
Insulin-sensitive fat leads to obesity
SORLA is a protein that influences the balance of metabolic processes in adipose tissue, a particular form of fat.
Is an insulin pump the best therapy for everyone with type 1 diabetes?
Insulin pump therapy contributes to better blood glucose control in type 1 diabetes and, as pump technology continues to improve and become part of sensor-controlled feedback and artificial pancreas systems, essentially all patients would benefit from their capabilities according to a Commentary published in Diabetes Technology & Therapeutics.

Related Insulin Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".